✦ LIBER ✦
5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
✍ Scribed by Loibl, S.; Pfisterer, J.; Wimberger, P.; Kurzeder, C.; Du Bois, A.; Sehouli, J.; Belau, A.; Burchardi, N.; Vergote, I.; Wagner, U.
- Book ID
- 123203125
- Publisher
- Elsevier Science
- Year
- 2007
- Tongue
- English
- Weight
- 59 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.